125 related articles for article (PubMed ID: 38083866)
21. Identification of Novel Natural Dual HDAC and Hsp90 Inhibitors for Metastatic TNBC Using e-Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Studies.
AbdElmoniem N; H Abdallah M; M Mukhtar R; Moutasim F; Rafie Ahmed A; Edris A; Ibraheem W; Makki AA; M Elshamly E; Elhag R; Osman W; A Mothana R; Alzain AA
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838758
[TBL] [Abstract][Full Text] [Related]
22. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.
Sadikot T; Swink M; Eskew JD; Brown D; Zhao H; Kusuma BR; Rajewski RA; Blagg BS; Matts RL; Holzbeierlein JM; Vielhauer GA
Assay Drug Dev Technol; 2013 Oct; 11(8):478-88. PubMed ID: 24127661
[TBL] [Abstract][Full Text] [Related]
23. Targeting the Hsp90 C-terminal domain by the chemically accessible dihydropyrimidinone scaffold.
Strocchia M; Terracciano S; Chini MG; Vassallo A; Vaccaro MC; Dal Piaz F; Leone A; Riccio R; Bruno I; Bifulco G
Chem Commun (Camb); 2015 Mar; 51(18):3850-3. PubMed ID: 25656927
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
Zhao H; Garg G; Zhao J; Moroni E; Girgis A; Franco LS; Singh S; Colombo G; Blagg BS
Eur J Med Chem; 2015 Jan; 89():442-66. PubMed ID: 25462258
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification.
Li L; Chen N; Xia D; Xu S; Dai W; Tong Y; Wang L; Jiang Z; You Q; Xu X
Cell Chem Biol; 2021 Oct; 28(10):1446-1459.e6. PubMed ID: 33932325
[TBL] [Abstract][Full Text] [Related]
26. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
27. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity.
Zhang Z; Banerjee M; Davis RE; Blagg BSJ
Bioorg Med Chem Lett; 2019 Nov; 29(22):126676. PubMed ID: 31591016
[TBL] [Abstract][Full Text] [Related]
29. Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.
Montoir D; Barillé-Nion S; Tonnerre A; Juin P; Duflos M; Bazin MA
Eur J Med Chem; 2016 Aug; 119():17-33. PubMed ID: 27153346
[TBL] [Abstract][Full Text] [Related]
30. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.
Liu W; Vielhauer GA; Holzbeierlein JM; Zhao H; Ghosh S; Brown D; Lee E; Blagg BS
Mol Pharmacol; 2015 Jul; 88(1):121-30. PubMed ID: 25939977
[TBL] [Abstract][Full Text] [Related]
31. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors.
Byrd KM; Kent CN; Blagg BSJ
ChemMedChem; 2017 Dec; 12(24):2022-2029. PubMed ID: 29058824
[TBL] [Abstract][Full Text] [Related]
33. Strategy of Virtual Screening based Discovery of HSP90 C-terminal Inhibitors and Network Pharmacological Analysis.
Li L; Yang M; Li C; Xue H; Shi M; Liu Y
Curr Pharm Biotechnol; 2022; 23(14):1637-1646. PubMed ID: 34514987
[TBL] [Abstract][Full Text] [Related]
34. Novobiocin Analogues That Inhibit the MAPK Pathway.
Hall JA; Seedarala S; Zhao H; Garg G; Ghosh S; Blagg BS
J Med Chem; 2016 Feb; 59(3):925-33. PubMed ID: 26745854
[TBL] [Abstract][Full Text] [Related]
35. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.
Eskew JD; Sadikot T; Morales P; Duren A; Dunwiddie I; Swink M; Zhang X; Hembruff S; Donnelly A; Rajewski RA; Blagg BS; Manjarrez JR; Matts RL; Holzbeierlein JM; Vielhauer GA
BMC Cancer; 2011 Oct; 11():468. PubMed ID: 22039910
[TBL] [Abstract][Full Text] [Related]
36. Alternative approaches to Hsp90 modulation for the treatment of cancer.
Hall JA; Forsberg LK; Blagg BS
Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors.
Bizarro A; Sousa D; Lima RT; Musso L; Cincinelli R; Zuco V; De Cesare M; Dallavalle S; Vasconcelos MH
Molecules; 2018 Feb; 23(2):. PubMed ID: 29438315
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
[TBL] [Abstract][Full Text] [Related]
39. Structure based design of heat shock protein 90 inhibitors acting as anticancer agents.
Doddareddy MR; Thorat DA; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
Bioorg Med Chem; 2011 Mar; 19(5):1714-20. PubMed ID: 21306907
[TBL] [Abstract][Full Text] [Related]
40. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors.
Saxena S; Chaudhaery SS; Varshney K; Saxena AK
SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
